PeptiDream

PeptiDream is a biopharmaceutical company founded in 2006 employing our proprietary Peptide Discovery Platform System (PDPS), a state-of-the-art highly versatile discovery platform which enables the production of highly diverse (trillions) non-standard peptide libraries with high efficiency, for the identification of highly potent and selective hit candidates, which then can be developed into peptide-based, small molecule-based, or peptide-drug-conjugate-based therapeutics.

Keiichi Masuya

COO

6 past transactions

Linqmed

Series B in 2025
Developer of radiopharmaceuticals intended to offer treatment of cancer. The company engages in the research and development of therapeutic and diagnostic drugs for cancer using 64Cu which is a radioisotope of copper, enabling doctors to provide cancer treatments to the patients.

Linqmed

Series B in 2025
Developer of radiopharmaceuticals intended to offer treatment of cancer. The company engages in the research and development of therapeutic and diagnostic drugs for cancer using 64Cu which is a radioisotope of copper, enabling doctors to provide cancer treatments to the patients.

Kleo

Series B in 2018
Kleo Pharmaceuticals, Inc. is a biotechnology company based in New Haven, Connecticut, focused on developing immunotherapies that harness small molecules to activate the immune system against cancer. Founded in 2015, Kleo is advancing two main types of compounds: Antibody Recruiting Molecules (ARMs) and Synthetic Antibody Mimics (SyAMs). These compounds are designed to be non-immunogenic, highly stable, and lower in molecular weight, allowing for faster and more cost-effective production. Kleo's technology aims to provide safer and more effective treatment options for cancer and infectious diseases, enabling medical practitioners to initiate tumor treatments promptly, thereby increasing the chances of successful outcomes. As of January 2021, Kleo operates as a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

Alivexis

Series A in 2018
Alivexis is a preclinical stage drug discovery company based in Tokyo, specializing in the rapid design and generation of small molecule clinical candidates aimed at addressing high-value disease targets. The company leverages advanced computational drug discovery techniques and unique biological insights to accelerate the development of new medicines. Its international team consists of experts in drug design and disease biology, drawing on extensive research and development experience from global pharmaceutical and biotechnology firms. Alivexis's platform is designed to enhance biotechnological research, ultimately enabling healthcare professionals to deliver effective treatments to patients with unmet medical needs.

PeptiStar

Corporate Round in 2018
PeptiStar is a CDMO (Contract Development and Manufacturing Organization) for peptide APIs, from traditional peptides to constrained peptides including macrocyclic and stapled peptides containing non-natural amino acids. PeptiStar is a technology-based company that provides its customers with high value-added services through its innovative manufacturing technologies.

PharmaDesign

Acquisition in 2015
PharmaDesign is a genomic drug discovery venture company.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.